Vident Investment Advisory LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,422 shares of the medical technology company’s stock, valued at approximately $486,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Koch Industries Inc. raised its position in Stryker by 34,120.3% in the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock valued at $1,252,000 after purchasing an additional 1,256,991 shares during the period. BlackRock Inc. increased its position in shares of Stryker by 5.2% during the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock worth $3,208,017,000 after acquiring an additional 1,139,082 shares during the period. Janus Henderson Group PLC increased its position in shares of Stryker by 2,237.8% during the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after acquiring an additional 975,656 shares during the period. Vanguard Group Inc. increased its position in shares of Stryker by 2.8% during the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock worth $3,341,643,000 after acquiring an additional 657,656 shares during the period. Finally, APG Asset Management N.V. increased its position in shares of Stryker by 117.1% during the third quarter. APG Asset Management N.V. now owns 583,736 shares of the medical technology company’s stock worth $82,902,000 after acquiring an additional 314,800 shares during the period. 74.97% of the stock is currently owned by institutional investors.
Stryker Corporation (NYSE:SYK) opened at $154.25 on Friday. The company has a market capitalization of $57,726.21, a price-to-earnings ratio of 24.45, a P/E/G ratio of 2.43 and a beta of 0.78. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. Stryker Corporation has a twelve month low of $116.50 and a twelve month high of $160.62.
Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. Stryker’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.39 earnings per share. equities analysts expect that Stryker Corporation will post 6.47 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio is 36.32%.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.40% of the company’s stock.
SYK has been the topic of a number of recent research reports. Wells Fargo & Company upped their price objective on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Cowen set a $160.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Friday, October 6th. Royal Bank of Canada reaffirmed a “buy” rating and set a $155.00 price objective on shares of Stryker in a research report on Monday, October 2nd. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price objective on shares of Stryker in a research report on Monday, October 2nd. Finally, Argus reaffirmed a “buy” rating and set a $160.00 price objective on shares of Stryker in a research report on Tuesday, August 29th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $153.19.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/17/vident-investment-advisory-llc-buys-new-stake-in-stryker-corporation-syk.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.